CDTX
NASDAQ
US
Cidara Therapeutics, Inc. - Common Stock
$221.38
+0.0 (+0.0%)
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$6.9B
ROE
-60.2%
Margin
-295.2%
D/E
0.00
Beta
1.54
52W
$15–$221
Wall Street Consensus
14 analysts · Apr 20263
Strong Buy
4
Buy
7
Hold
0
Sell
0
Strong Sell
50.0%
Buy Rating
Price Chart
Similar Stocks
KRYS
Krystal Biotech Inc
P/E 35.9
$7.1B
HALO
Halozyme Therapeutics Inc
P/E 13.3
$7.9B
IBRX
Immunitybio Inc
$2.0B
KYMR
Kymera Therapeutics Inc
$6.1B
ACLX
Arcellx Inc
$3.8B
PTGX
Protagonist Therapeutics Inc
P/E 118.9
$5.5B
RYTM
Rhythm Pharmaceuticals Inc
$7.1B
SRRK
Scholar Rock Holding Corp
$4.5B
COGT
Cogent Biosciences Inc
$5.4B
CGON
CG Oncology Inc
$3.3B
Earnings
Beat rate: 50.0%
Next Report
May 06, 2026
EPS Estimate: $-1.37
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.37 | — | — |
| Sep 2025 | $-1.37 | $-3.10 | $-1.73 |
| Jun 2025 | $-2.03 | $-1.65 | +$0.38 |
| Mar 2025 | $-3.61 | $-1.66 | +$1.95 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -51.0% | -51.0% | -51.0% | -51.0% | -60.2% | -60.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -295.2% | -295.2% | -295.2% | -295.2% | -295.2% |
| Gross Margin | — | 92.0% | 92.0% | 92.0% | 92.0% | 92.0% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 16.45 | 16.45 | 16.45 | 16.45 | 4.62 | 4.62 |
Key Ratios
ROA (TTM)
-50.6%
P/S (TTM)
177.77
P/B
1.8
EPS (TTM)
$-11.77
CF/Share
$-0.35
Rev Growth 3Y
-70.5%
52W High
$221.20
52W Low
$15.22
$15.22
52-Week Range
$221.20
How does CDTX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CDTX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
177.8
▲
1283%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
1.8
▼
27%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CDTX profitability vs Biotechnology peers
ROE
-60.2%
▲
11%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-295.2%
▼
3%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
92.0%
▲
17%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-50.6%
▼
8%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
CDTX financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.6
▲
4%
above
peers
(4.4)
vs Peers
vs Industry
In line
Beta
1.5
▲
59%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CDTX fundamentals radar
CDTX
Peer median
Industry
CDTX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CDTX vs peers: key metrics
Latest News
No related news yet